AtaiBeckley Inc. participated in the 64th Annual Meeting of the American College of Neuropsychopharmacology, which took place January 12-15, 2026, in Nassau, the Bahamas. The company presented clinical and preclinical data in two poster presentations and a Hot Topic Presentation supporting development of mental health therapies.
Dr. David Feifel, Professor Emeritus of Psychiatry at the University of California, San Diego, presented efficacy and safety data from AtaiBeckley’s Phase 2b study of BPL-003 (mebufotenin benzoate) nasal spray in patients with treatment-resistant depression. The poster, titled “Rapid Antidepressant Effect of Intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in Treatment-Resistant Depression: A Phase 2b Double-Blind Study,” was selected for the prestigious Hot Topics Session—reserved for the most compelling findings.
The study showed a single 8 mg or 12 mg dose of BPL-003 resulted in significant, rapid, and sustained antidepressant effect compared with a 0.3 mg sub-perceptual dose control at all timepoints. Both active dose levels were well-tolerated, indicating potential benefits of intranasal BPL-003 and highlighting need for further Phase 3 investigation.
Dr. Michelle Kokkinou, Senior Scientist at AtaiBeckley, presented a preclinical poster investigating the pharmacological, pharmacokinetic, and potential neuroplasticity-related profile of 5-MeO-DMT. Findings support effects potentially relevant to therapeutic use for mood disorders, highlighting approaches for targeting neuroplasticity alterations implicated in individuals with mood disorders. BPL-003 has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration and is covered by granted U.S., U.K., and European composition-of-matter patents.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.benzinga.com/pressreleases/26/01/g49960316/ataibeckley-participates-in-the-64th-annual-acnp-meeting-with-two-scientific-poster-presentations-